{
    "title": "What is cancer? A focus on Grade Group 1 prostate cancer.",
    "doc_id": "38229478",
    "writer": "Talwar R",
    "year": "2024",
    "summary": "Since the widespread adoption of prostate-specific antigen-based screening for prostate cancer, the prevalence of Grade Group 1 (GG1) prostate cancer has risen. ...Here we provide a comprehensive overview of the characteristics of GG1 prostat â€¦",
    "abstract": "Since the widespread adoption of prostate-specific antigen-based screening for prostate cancer, the prevalence of Grade Group 1 (GG1) prostate cancer has risen. Historically, these patients were subjected to overtreatment of this otherwise indolent disease process, leading to significant quality-of-life detriments. Active surveillance as a primary management strategy has allowed for a focus on early detection while minimising morbidity from unnecessary intervention. Here we provide a comprehensive overview of the characteristics of GG1 prostatic adenocarcinoma, including its histological features, genomic differentiators, clinical progression, and implications for treatment guidelines, all supporting the movement to reclassify GG1 disease as a non-cancerous entity.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/38229478/"
}